Request for Proposal: Accelerating Drug Discovery for Frontotemporal Degeneration
Research investigating the pathologic mechanisms underlying frontotemporal degeneration (FTD) is advancing, creating new targets for drug discovery. The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate and support innovative drug discovery programs for FTD through this Request for Proposals (RFP).
Average Duration: 1 year
Average Award: $100,000-$150,000
Must be received by 11:59 pm EST on the deadline date.
Letter of Intent: July 31, 2017
Invited Full Proposal: September 8, 2017
- Development and testing of novel high throughput screening assays
- Identification and in vitro testing of potentially disease modifying compounds or biologics, including medicinal chemistry refinement, ADME, toxicology, pharmacokinetics, and pharmacodynamics studies
- Testing of novel lead compounds, biologics, or repurposed drug candidates in a relevant animal model for preclinical proof of concept
- Development and/or characterization of new model organisms or cellular models to support drug discovery efforts.
- Academic investigators seeking to create and support innovative translational programs in academic medical centers and universities.
- Biotechnology companies with programs dedicated to neurodegenerative disease translational development. New biotechnology company spinouts or existing biotechnology companies that demonstrate a clear need for non-profit funding are eligible to apply. Funding is provided through program-related investments (PRIs) that require return on investment based upon scientific and/or business milestones.
Application Submission Guidelines
The ADDF typically supports one year of research at a time, with potential for future follow-on funding. Funding can range from $100,000-$150,000 per year for a preclinical project depending on the stage of research and must be justified based on the scientific work plan. Applications will be confidentially reviewed by the ADDF and an external Scientific Review Committee, including members of AFTD's Medical Advisory Council. Applications from biotechnology companies will also be reviewed by ADDF's external Business Advisory Board.
All applicants are required to complete an electronic "Letter of Intent" (LOI) available through the links below.
Applicants are encouraged to sign up for the ADDF ACCESS portal to gain access to an online marketplace of contract research organizations (CROs) and a virtual network of experts and educational resources. For guidance on selecting and managing CROs, please see ADDF's publication.
For program-related inquiries, please contact:
Diana Shineman, PhD, Senior Director for Scientific Affairs, ADDF
Nadine Tatton, PhD, Scientific Director, AFTD
For application submission inquiries, please contact:
Grants and Contracts Team